Forte Capital LLC ADV Acquires 148 Shares of Zoetis Inc. (NYSE:ZTS)

Forte Capital LLC ADV grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,211 shares of the company’s stock after buying an additional 148 shares during the period. Forte Capital LLC ADV’s holdings in Zoetis were worth $360,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Hancock Whitney Corp boosted its holdings in shares of Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after buying an additional 61 shares in the last quarter. Strategy Asset Managers LLC lifted its holdings in shares of Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares in the last quarter. VeraBank N.A. lifted its holdings in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC lifted its holdings in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Aberdeen Wealth Management LLC lifted its holdings in shares of Zoetis by 1.9% in the 3rd quarter. Aberdeen Wealth Management LLC now owns 3,566 shares of the company’s stock worth $697,000 after purchasing an additional 68 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Zoetis Trading Up 1.9 %

Shares of ZTS opened at $160.39 on Friday. The business has a 50-day moving average of $166.51 and a 200 day moving average of $178.04. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The firm has a market cap of $71.82 billion, a P/E ratio of 29.32, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.25%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ZTS. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average target price of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.